Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development
On May 11, 2020, the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation (Gates Foundation) held an exploratory expert scientific roundtable to inform an NIH-Gates Foundation collaboration on the development of scalable, sustainable, and accessible HIV and sickle cell dis...
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Mary Ann Liebert Inc
2021
|
| Acesso em linha: | https://hdl.handle.net/1721.1/133085 |
| _version_ | 1826211376793649152 |
|---|---|
| author | Cannon, Paula Asokan, Aravind Czechowicz, Agnieszka Hammond, Paula Kohn, Donald B Lieber, Andre Malik, Punam Marks, Peter Porteus, Matthew Verhoeyen, Els Weissman, Drew Weissman, Irving Kiem, Hans-Peter |
| author_facet | Cannon, Paula Asokan, Aravind Czechowicz, Agnieszka Hammond, Paula Kohn, Donald B Lieber, Andre Malik, Punam Marks, Peter Porteus, Matthew Verhoeyen, Els Weissman, Drew Weissman, Irving Kiem, Hans-Peter |
| author_sort | Cannon, Paula |
| collection | MIT |
| description | On May 11, 2020, the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation (Gates Foundation) held an exploratory expert scientific roundtable to inform an NIH-Gates Foundation collaboration on the development of scalable, sustainable, and accessible HIV and sickle cell disease (SCD) therapies based on in vivo gene editing of hematopoietic stem cells (HSCs). A particular emphasis was on how such therapies could be developed for low-resource settings in sub-Saharan Africa. Paula Cannon, PhD, of the University of Southern California and Hans-Peter Kiem, MD, PhD, of the Fred Hutchinson Cancer Research Center served as roundtable cochairs. Welcoming remarks were provided by the leadership of NIH, NHLBI, and BMGF, who cited the importance of assessing the state of the science and charting a path toward finding safe, effective, and durable gene-based therapies for HIV and SCD. These remarks were followed by three sessions in which participants heard presentations on and discussed the therapeutic potential of modified HSCs, leveraging HSC biology and differentiation, and in vivo HSC targeting approaches. This roundtable serves as the beginning of an ongoing discussion among NIH, the Gates Foundation, research and patient communities, and the public at large. As this collaboration progresses, these communities will be engaged as we collectively navigate the complex scientific and ethical issues surrounding in vivo HSC targeting and editing. Summarized excerpts from each of the presentations are given hereunder, reflecting the individual views and perspectives of each presenter. |
| first_indexed | 2024-09-23T15:05:16Z |
| format | Article |
| id | mit-1721.1/133085 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T15:05:16Z |
| publishDate | 2021 |
| publisher | Mary Ann Liebert Inc |
| record_format | dspace |
| spelling | mit-1721.1/1330852022-01-24T03:48:59Z Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development Cannon, Paula Asokan, Aravind Czechowicz, Agnieszka Hammond, Paula Kohn, Donald B Lieber, Andre Malik, Punam Marks, Peter Porteus, Matthew Verhoeyen, Els Weissman, Drew Weissman, Irving Kiem, Hans-Peter On May 11, 2020, the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation (Gates Foundation) held an exploratory expert scientific roundtable to inform an NIH-Gates Foundation collaboration on the development of scalable, sustainable, and accessible HIV and sickle cell disease (SCD) therapies based on in vivo gene editing of hematopoietic stem cells (HSCs). A particular emphasis was on how such therapies could be developed for low-resource settings in sub-Saharan Africa. Paula Cannon, PhD, of the University of Southern California and Hans-Peter Kiem, MD, PhD, of the Fred Hutchinson Cancer Research Center served as roundtable cochairs. Welcoming remarks were provided by the leadership of NIH, NHLBI, and BMGF, who cited the importance of assessing the state of the science and charting a path toward finding safe, effective, and durable gene-based therapies for HIV and SCD. These remarks were followed by three sessions in which participants heard presentations on and discussed the therapeutic potential of modified HSCs, leveraging HSC biology and differentiation, and in vivo HSC targeting approaches. This roundtable serves as the beginning of an ongoing discussion among NIH, the Gates Foundation, research and patient communities, and the public at large. As this collaboration progresses, these communities will be engaged as we collectively navigate the complex scientific and ethical issues surrounding in vivo HSC targeting and editing. Summarized excerpts from each of the presentations are given hereunder, reflecting the individual views and perspectives of each presenter. 2021-10-25T15:53:38Z 2021-10-25T15:53:38Z 2021 2021-06-10T16:02:15Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/133085 Cannon, Paula, Asokan, Aravind, Czechowicz, Agnieszka, Hammond, Paula, Kohn, Donald B et al. 2021. "Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development." Human Gene Therapy, 32 (1-2). en 10.1089/hum.2020.263 Human Gene Therapy Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf Mary Ann Liebert Inc Mary Ann Liebert |
| spellingShingle | Cannon, Paula Asokan, Aravind Czechowicz, Agnieszka Hammond, Paula Kohn, Donald B Lieber, Andre Malik, Punam Marks, Peter Porteus, Matthew Verhoeyen, Els Weissman, Drew Weissman, Irving Kiem, Hans-Peter Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title | Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title_full | Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title_fullStr | Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title_full_unstemmed | Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title_short | Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development |
| title_sort | safe and effective in vivo targeting and gene editing in hematopoietic stem cells strategies for accelerating development |
| url | https://hdl.handle.net/1721.1/133085 |
| work_keys_str_mv | AT cannonpaula safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT asokanaravind safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT czechowiczagnieszka safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT hammondpaula safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT kohndonaldb safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT lieberandre safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT malikpunam safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT markspeter safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT porteusmatthew safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT verhoeyenels safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT weissmandrew safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT weissmanirving safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment AT kiemhanspeter safeandeffectiveinvivotargetingandgeneeditinginhematopoieticstemcellsstrategiesforacceleratingdevelopment |